The purpose of this study is to find out whether it is safe and practical to perform MIDCAB surgery (a minimally invasive heart bypass procedure) while patients receive a continuous cangrelor infusion during the operation. Cangrelor is a medicine that helps prevent blood clots and works quickly through a vein drip.
The study compares patients receiving cangrelor during surgery to patients who had the same surgery in the past while on aspirin, with or without cangrelor given beforehand.
Study Question: Can MIDCAB surgery be safely performed under cangrelor infusion, without increasing the risk of bleeding or other complications?
Hypothesis: Using cangrelor during MIDCAB surgery is safe and feasible, and it provides effective protection against blood clots during the procedure.
This study will help doctors understand whether intraoperative cangrelor can improve patient safety and outcomes in minimally invasive heart surgery.
Age ≥18 years old
CABG with IMA-LAD graft in MIDCAB technique
Age ≥18 years old
CABG with IMA-LAD graft in MIDCAB technique
Administration of fibrinolytics or GP IIb/IIIa inhibitors
Previous intracranial hemorrhage
Known bleeding diathesis
Patients undergoing concomitant PCI and MIDCAB